Guillain-Barré Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon

Guillain-Barré Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon
The Guillain-Barré Syndrome Market Forecast report offers an in-depth understanding of the Guillain-Barré Syndrome, historical and forecasted epidemiology as well as the Guillain-Barré Syndrome market trends in the 7MM.

DelveInsight’s “Guillain-Barré Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Guillain-Barré Syndrome, historical and forecasted epidemiology as well as the Guillain-Barré Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Guillain-Barré Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Guillain-Barré Syndrome Market Forecast

 

Some of the key facts of the Guillain-Barré Syndrome Market Report: 

  • The Guillain-Barré Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In December 2023, Hansa Biopharma, known as “Hansa,” released encouraging preliminary findings from the phase 2 trial 15-HMedIdeS-09, showcasing the safety and tolerability of imlifidase alongside standard care. The trial demonstrated swift enhancements in disease-related effectiveness measures. Further evaluation of the efficacy data is scheduled for 2024. The 15-HMedIdeS-09 trial, designed as an open-label, single-arm study, evaluates the safety, tolerance, and efficacy of imlifidase in patients with Guillain-Barré Syndrome (GBS) in conjunction with standard intravenous immunoglobulin (IVIg) treatment.
  • In October 2023, Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical firm specializing in novel complement-based therapies for autoimmune, neurodegenerative, and ophthalmic ailments, disclosed that the European Medicines Agency (EMA) has awarded orphan drug status to ANX005 for Guillain-Barré Syndrome (GBS) treatment. Previously, the U.S. Food and Drug Administration (FDA) had also granted ANX005 orphan drug status for GBS treatment.
  • As per the National Organization of Rare Disorders (NORD) (n.d.), Guillain-Barré Syndrome (GBS) impacts approximately one to two individuals annually per 100,000 population. The precise cause of this condition remains uncertain. It’s noted that around half of those affected experience a gastrointestinal or respiratory infection in the days leading up to the onset of symptoms.
  • The outlook for Guillain-Barré Syndrome (GBS) varies depending on its specific form. While some patients achieve full recovery, others may still face challenges with walking six months after the onset of the disease. In severe cases, GBS can unfortunately lead to a fatal outcome.
  • Key Guillain-Barré Syndrome Companies: Chafic Karam, Hansa Biopharma AB, Annexon, and others
  • Key Guillain-Barré Syndrome Therapies: Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others
  • The Guillain-Barré Syndrome epidemiology based on gender analyzed that Guillain-Barré Syndrome is more common in men than in women
  • The Guillain-Barré Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Guillain-Barré Syndrome pipeline products will significantly revolutionize the Guillain-Barré Syndrome market dynamics.

 

Guillain-Barré Syndrome Overview

Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the body’s immune system mistakenly attacks its nerves. This condition leads to muscle weakness, numbness, and in some cases, paralysis. GBS often begins with tingling sensations and weakness in the legs, which can rapidly progress to affect the arms and upper body. In severe cases, GBS can cause paralysis of the entire body, including the muscles involved in breathing, requiring hospitalization and sometimes intensive care.

 

Get a Free sample for the Guillain-Barré Syndrome Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market

 

Guillain-Barré Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Guillain-Barré Syndrome Epidemiology Segmentation:

The Guillain-Barré Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Guillain-Barré Syndrome
  • Prevalent Cases of Guillain-Barré Syndrome by severity
  • Gender-specific Prevalence of Guillain-Barré Syndrome
  • Diagnosed Cases of Episodic and Chronic Guillain-Barré Syndrome

 

Download the report to understand which factors are driving Guillain-Barré Syndrome epidemiology trends @ Guillain-Barré Syndrome Epidemiology Forecast

 

Guillain-Barré Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barré Syndrome market or expected to get launched during the study period. The analysis covers Guillain-Barré Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Guillain-Barré Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Guillain-Barré Syndrome Therapies and Key Companies

  • Efgartigimod Alfa-Fcab: Chafic Karam
  • Imlifidase: Hansa Biopharma AB
  • ANX005: Annexon, Inc.

 

Discover more about therapies set to grab major Guillain-Barré Syndrome market share @ Guillain-Barré Syndrome Treatment Landscape 

 

Scope of the Guillain-Barré Syndrome Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Guillain-Barré Syndrome Companies: Chafic Karam, Hansa Biopharma AB, Annexon, Inc., and others
  • Key Guillain-Barré Syndrome Therapies: Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others
  • Guillain-Barré Syndrome Therapeutic Assessment: Guillain-Barré Syndrome current marketed and Guillain-Barré Syndrome emerging therapies
  • Guillain-Barré Syndrome Market Dynamics: Guillain-Barré Syndrome market drivers and Guillain-Barré Syndrome market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Guillain-Barré Syndrome Unmet Needs, KOL’s views, Analyst’s views, Guillain-Barré Syndrome Market Access and Reimbursement 

 

To know more about Guillain-Barré Syndrome companies working in the treatment market, visit @ Guillain-Barré Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Guillain-Barré Syndrome Market Report Introduction

2. Executive Summary for Guillain-Barré Syndrome

3. SWOT analysis of Guillain-Barré Syndrome

4. Guillain-Barré Syndrome Patient Share (%) Overview at a Glance

5. Guillain-Barré Syndrome Market Overview at a Glance

6. Guillain-Barré Syndrome Disease Background and Overview

7. Guillain-Barré Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Guillain-Barré Syndrome 

9. Guillain-Barré Syndrome Current Treatment and Medical Practices

10. Guillain-Barré Syndrome Unmet Needs

11. Guillain-Barré Syndrome Emerging Therapies

12. Guillain-Barré Syndrome Market Outlook

13. Country-Wise Guillain-Barré Syndrome Market Analysis (2019–2032)

14. Guillain-Barré Syndrome Market Access and Reimbursement of Therapies

15. Guillain-Barré Syndrome Market Drivers

16. Guillain-Barré Syndrome Market Barriers

17.  Guillain-Barré Syndrome Appendix

18. Guillain-Barré Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: